KR100634926B1 - 혈관 내피 세포 성장 인자 변이체 및 그의 용도 - Google Patents

혈관 내피 세포 성장 인자 변이체 및 그의 용도 Download PDF

Info

Publication number
KR100634926B1
KR100634926B1 KR1020017013112A KR20017013112A KR100634926B1 KR 100634926 B1 KR100634926 B1 KR 100634926B1 KR 1020017013112 A KR1020017013112 A KR 1020017013112A KR 20017013112 A KR20017013112 A KR 20017013112A KR 100634926 B1 KR100634926 B1 KR 100634926B1
Authority
KR
South Korea
Prior art keywords
vegf
amino acid
flt
delete delete
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020017013112A
Other languages
English (en)
Korean (ko)
Other versions
KR20020008151A (ko
Inventor
브라이언 커닝햄
아브라함 데보스
빙 리
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20020008151A publication Critical patent/KR20020008151A/ko
Application granted granted Critical
Publication of KR100634926B1 publication Critical patent/KR100634926B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020017013112A 1999-04-16 2000-04-10 혈관 내피 세포 성장 인자 변이체 및 그의 용도 Expired - Lifetime KR100634926B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12978899P 1999-04-16 1999-04-16
US60/129,788 1999-04-16
US18423500P 2000-02-23 2000-02-23
US60/184,235 2000-02-23
PCT/US2000/009483 WO2000063380A1 (en) 1999-04-16 2000-04-10 Vascular endothelial cell growth factor variants and uses thereof

Publications (2)

Publication Number Publication Date
KR20020008151A KR20020008151A (ko) 2002-01-29
KR100634926B1 true KR100634926B1 (ko) 2006-10-17

Family

ID=26827914

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017013112A Expired - Lifetime KR100634926B1 (ko) 1999-04-16 2000-04-10 혈관 내피 세포 성장 인자 변이체 및 그의 용도

Country Status (15)

Country Link
US (1) US20060063203A1 (enExample)
EP (2) EP1655368B1 (enExample)
JP (1) JP2002541849A (enExample)
KR (1) KR100634926B1 (enExample)
CN (1) CN1328376C (enExample)
AT (2) ATE420177T1 (enExample)
AU (1) AU771042B2 (enExample)
CA (1) CA2370246C (enExample)
DE (2) DE60041367D1 (enExample)
ES (2) ES2265931T3 (enExample)
HU (1) HU228898B1 (enExample)
IL (2) IL145675A0 (enExample)
MX (1) MXPA01010469A (enExample)
NZ (1) NZ514488A (enExample)
WO (1) WO2000063380A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
WO2001032695A2 (en) * 1999-11-02 2001-05-10 Genentech, Inc. MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1572724A4 (en) * 2002-03-01 2007-03-14 Dyax Corp KDR AND VEGF / KDR BINDING SPEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
AU2003228276B8 (en) 2002-03-01 2010-02-18 Bracco Suisse S.A. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2003103581A2 (en) 2002-06-05 2003-12-18 Genentech, Inc. Compositions and methods for liver growth and liver protection
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7632810B2 (en) 2003-03-12 2009-12-15 Genentech, Inc. Compositions with hematopoietic and immune activity
ATE456579T1 (de) 2004-07-20 2010-02-15 Genentech Inc Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
NZ552957A (en) 2004-07-20 2011-06-30 Genentech Inc Compositions and methods of using angiopoietin-like 4 protein
PL1861116T3 (pl) 2005-03-25 2016-02-29 Regeneron Pharma Formulacje antagonistów VEGF
WO2007109183A2 (en) * 2006-03-20 2007-09-27 Novartis Ag Mutations and polymorphisms of fms-related tyrosine kinase 1
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169292A (en) * 1875-10-26 Improvement in butter-packages
DK0751992T3 (da) * 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
CN1185159A (zh) * 1995-06-06 1998-06-17 人体基因组科学有限公司 人血管内皮生长因子3
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids

Also Published As

Publication number Publication date
AU4222000A (en) 2000-11-02
ATE420177T1 (de) 2009-01-15
CA2370246A1 (en) 2000-10-26
WO2000063380A1 (en) 2000-10-26
EP1655368A1 (en) 2006-05-10
EP1171594B1 (en) 2006-06-07
IL145675A0 (en) 2002-06-30
MXPA01010469A (es) 2002-07-30
CN1352684A (zh) 2002-06-05
KR20020008151A (ko) 2002-01-29
DE60028565D1 (de) 2006-07-20
HUP0200827A2 (en) 2002-06-29
IL145675A (en) 2010-11-30
CN1328376C (zh) 2007-07-25
ATE329024T1 (de) 2006-06-15
ES2320367T3 (es) 2009-05-21
CA2370246C (en) 2017-03-21
US20060063203A1 (en) 2006-03-23
DE60041367D1 (de) 2009-02-26
AU771042B2 (en) 2004-03-11
ES2265931T3 (es) 2007-03-01
JP2002541849A (ja) 2002-12-10
HK1093218A1 (en) 2007-02-23
EP1171594A1 (en) 2002-01-16
EP1655368B1 (en) 2009-01-07
HUP0200827A3 (en) 2004-11-29
HU228898B1 (en) 2013-06-28
NZ514488A (en) 2004-01-30
DE60028565T2 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
KR100634926B1 (ko) 혈관 내피 세포 성장 인자 변이체 및 그의 용도
EP0851920B1 (en) Variants of vascular endothelial cell growth factor, their uses, and processes for their porduction
US6750044B1 (en) Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US7005505B1 (en) Variants of vascular endothelial cell growth factor
US6395707B1 (en) Methods of treatment utilizing variants of vascular endothelial cell growth factor
US7090834B1 (en) Vascular endothelial cell growth factor variants and uses thereof
WO1998036075A9 (en) Variants of vascular endothelial cell growth factor having altered pharmacological properties, and related aspects thereof
US7078382B1 (en) Modulation of eNOS activity and therapeutic uses thereof
AU2004202596B2 (en) Vascular endothelial cell growth factor variants and uses thereof
AU782158B2 (en) Modulation of eNOS activity and therapeutic uses thereof
HK1093218B (en) Vascular endothelial cell growth factor variants and uses thereof
CN101070343A (zh) 血管内皮细胞生长因子变体及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20011015

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050411

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060525

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20060731

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20061010

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20061011

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20090925

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20101007

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20110920

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20120924

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20120924

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20130927

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20130927

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20140929

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20140929

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20150930

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20150930

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20160929

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20160929

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20170929

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20170929

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20180928

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20180928

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20190924

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20190924

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20201010

Termination category: Expiration of duration